Bristol-Myers, Celgene to Tie a $74 Billion Knot
Bristol-Myers has announced a definitive agreement to acquire rival Celgene in a cash and stock deal worth $74 billion. Celgene shareholders are scheduled to receive a 54% premium to Wednesday night's closing stock price.















